7th Annual Heart in Diabetes (HiD)


  • 公開的
  • June 09 2023 9:00 AM - June 11 2023 6:00 PM ((GMT+08:00) Hong Kong)
  • Philadelphia, PA
  • Pennsylvania (查看地圖)
  • 7th Annual Heart in Diabetes (HiD)

    June 9-11, 2023

    Philadelphia, PA

    7th Annual Heart in Diabetes (HiD) CME Conference, a unique and exciting multidisciplinary program: Where the Heart, Kidney, and Diabetes Meet in Clinical Practice.

    For half a decade, the annual Heart in Diabetes (HID) Congress has brought together internationally known experts with practicing clinicians to share knowledge and best practices for managing patients with cardio-renal-metabolic disorders. This one-of-a-kind meeting has become an important venue where clinicians from multiple specialties work together to improve care for patients with diabetes, cardiovascular disease (CVD), chronic kidney disease (CKD), heart failure (HF), and related conditions. Until recently, these conditions were treated as separate diseases and largely managed by different specialists with different clinical priorities and goals. The HID platform facilitates an approach based on the common pathways underlying cardiorenal and metabolic diseases. To continue to promote synergy in patient care, the cardio-renal-metabolic community will gather once again at the 7th Annual Heart in Diabetes. The meeting will take place June 9-11, 2023, in Philadelphia, PA.

    Program Description

    The Heart in Diabetes (HiD) conference, entering its sixth year, is a unique medical meeting that brings world-renowned clinical leaders in diabetes, obesity and cardiorenal metabolic diseases together with practicing clinicians to improve the care of patients at a high risk of these comorbidities. 

    This program is designed to evaluate the clinical science aspects of recent cardiovascular outcome trials (CVOTs) and their impact on the prevention and treatment of diabetes, ASCVD, heart failure, kidney and metabolic diseases. The goal is to develop appropriate comprehensive management plans aligning endocrinologists, cardiologists, nephrologists, and all other interested clinicians in their understanding of the new data’s implications on the clinical management of these very high-risk patients.